65% of Americans say that healthcare is too expensive and almost 9% of adults have no medical insurance coverage. In fact, more than one third of Americans have claimed not to visit their doctor when they should have because of cost. Bongiovi Acoustic Labs aims to show that audio technology can be applied affordably to medical devices, to make healthcare more accessible.

Bongiovi's algorithm has the ability to remaster audio in real time. It allows the Aria to instantly map the shortcomings lost in digital conversation, restore frequency responses and deliver advanced audio quality. Through our customized telemedicine platform, the Aria offers remote patient monitoring to healthcare professionals and patients across the globe.

Right from inception, it was very important for us to empathize with our consumers while we define the scope, competition and culture in which the Aria belongs. By combining carefully studied ergonomics and user experience in the fields of audio technology and healthcare, we discovered new possibilities for Bongiovi in the future of telemedicine.

In order to maintain cost-efficiency and maximize reach, we chose to design the platform for Android devices. Most of the device’s functionality, like hearing, visualizing, recording, and storing patient data is possible without an internet connection, but once connected those file can be shared.

The current design is scalable into a number of specific use cases and price points. These include clinical, telemedicine, rural medicine and home healthcare. The MDPS software, via medical research, can and will be expanded to develop new ways of listening and analyzing biological sounds.

Through our strategic partnership, we’re able to move Bongiovi Acoustic Labs’ technology into the world of healthcare. Based on the conservative pricing of the Aria, almost 160,000 doctors in the US are likely to find the product’s proposition relevant for benefits that impact both a healthy community and a healthy wallet, proving that cost-effective telemedicine can be profitable. Focusing only on two relevant patient diagnoses, Heart Disease and COPD, Aria may be able to positively impact almost 4mm US adult patients (1.5mm on Medicare/Medicaid and 2.4mm with other insurances). Medicare and Medicaid patients benefiting from the use of the modestly priced Aria could also simultaneously generate $222.6mm with device sales, while doctors could receive $1.1bn from US government for monitoring device outputs. If incentives extend to Group/Non-Group insureds, an additional $2.1bn dollars could be generated.